ENZN Enzon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. OTC: ENZN

Price (delayed)

$0.1445

Market cap

$10.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

$0

Enterprise value

-$35.41M

Highlights
Enzon Pharmaceuticals's net income has surged by 172% YoY and by 131% QoQ
The company's EPS has surged by 100% QoQ and by 100% YoY
ENZN's quick ratio is down by 8% year-on-year but it is up by 2.1% since the previous quarter
The equity has contracted by 17% YoY and by 11% from the previous quarter
ENZN's revenue is down by 10% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://enzon.com/
Peers: NKTR AMGN ENTA XOMA

Key stats

What are the main financial stats of ENZN
Market
Shares outstanding
74.21M
Market cap
$10.72M
Enterprise value
-$35.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.94
Price to sales (P/S)
412.46
EV/EBIT
-68.22
EV/EBITDA
-68.22
EV/Sales
-1,361.81
Earnings
Revenue
$26,000
EBIT
$519,000
EBITDA
$519,000
Free cash flow
$612,000
Per share
EPS
$0
Free cash flow per share
$0.01
Book value per share
$0.04
Revenue per share
$0
TBVPS
$0.63
Balance sheet
Total assets
$46.67M
Total liabilities
$43.95M
Debt
$0
Equity
$2.73M
Working capital
$46.08M
Liquidity
Debt to equity
0
Current ratio
115.63
Quick ratio
114.75
Net debt/EBITDA
-88.88
Margins
EBITDA margin
1,996.2%
Gross margin
100%
Net margin
2,684.6%
Operating margin
-8,596.2%
Efficiency
Return on assets
-1.2%
Return on equity
-19.3%
Return on invested capital
N/A
Return on capital employed
1.1%
Return on sales
1,996.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZN stock price

How has the Enzon Pharmaceuticals stock price performed over time
Intraday
3.44%
1 week
6.25%
1 month
-3.67%
1 year
-46.48%
YTD
-41.43%
QTD
-27.75%

Financial performance

How have Enzon Pharmaceuticals's revenue and profit performed over time
Revenue
$26,000
Gross profit
$26,000
Operating income
-$2.24M
Net income
$698,000
Gross margin
100%
Net margin
2,684.6%
ENZN's net margin has surged by 181% year-on-year and by 131% since the previous quarter
Enzon Pharmaceuticals's net income has surged by 172% YoY and by 131% QoQ
ENZN's revenue is down by 10% year-on-year
The gross profit has contracted by 10% YoY

Growth

What is Enzon Pharmaceuticals's growth rate over time

Valuation

What is Enzon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.94
P/S
412.46
EV/EBIT
-68.22
EV/EBITDA
-68.22
EV/Sales
-1,361.81
The company's EPS has surged by 100% QoQ and by 100% YoY
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 6.2 but 3.7% more than its 5-year quarterly average of 3.8
The equity has contracted by 17% YoY and by 11% from the previous quarter
The P/S is 76% above the 5-year quarterly average of 233.9 but 40% below the last 4 quarters average of 685.6
ENZN's revenue is down by 10% year-on-year

Efficiency

How efficient is Enzon Pharmaceuticals business performance
The company's return on sales has surged by 160% YoY
ENZN's return on assets has surged by 81% year-on-year and by 43% since the previous quarter
Enzon Pharmaceuticals's return on equity has surged by 72% YoY and by 38% QoQ

Dividends

What is ENZN's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Enzon Pharmaceuticals financials performed over time
Enzon Pharmaceuticals's total assets is 6% more than its total liabilities
The current ratio has decreased by 8% YoY
ENZN's quick ratio is down by 8% year-on-year but it is up by 2.1% since the previous quarter
ENZN's debt is 100% smaller than its equity
The equity has contracted by 17% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.